Dupixent 200 mg solution for injection in pre-filled pen

DRUG4 trials

Sponsors

Centre Hospitalier Universitaire De Nantes, Regeneron Pharmaceuticals Inc., Medical University Of Vienna, Amsterdam UMC Stichting

Conditions

Atopic DermatitisChronic Rhinosinusitis with Nasal PolypsSevere Asthmaatopic dermatitis

Phase 3

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis.

Active, not recruitingCTIS2023-509425-53-00

Regeneron Pharmaceuticals Inc.Atopic Dermatitis

Start: 2015-11-09Target: 201Updated: 2025-11-04

Phase 4

Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized trial

Active, not recruitingCTIS2022-501179-23-00

Centre Hospitalier Universitaire De Nantesatopic dermatitis

Start: 2023-03-08Target: 256Updated: 2025-07-11

Direct comparison of Tezepelumab and Dupilumab in CRSwNP in a real world setting

Not yet recruitingCTIS2025-524495-39-00

Medical University Of ViennaChronic Rhinosinusitis with Nasal Polyps

Target: 220Updated: 2026-03-22

BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)

Not yet recruitingCTIS2025-524741-28-00

Amsterdam UMC StichtingSevere Asthma

Target: 142Updated: 2026-06-05

Related Papers

Dupilumab step-down strategy to maintain remission in adult and adolescent patients with atopic dermatitis: study protocol for a non-inferiority randomized trial (MADULO).

2025-12-05